Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Alzheimer's
Pharma
Axsome's Auvelity wins FDA expansion for Alzheimer's agitation
Axsome Therapeutics has gained FDA approval for its first-in-class Auvelity to treat agitation associated with Alzheimer’s disease.
Kevin Dunleavy
May 1, 2026 11:42am
With trial looming, Biogen and investors settle Aduhelm claims
Apr 8, 2026 11:28am
Analysts tip Lilly's Alzheimer's launch to boost rival Leqembi
Jun 12, 2024 9:29am
Lilly tipped to beat Eisai, Biogen, win $13B Alzheimer's fight
Jun 7, 2024 4:51am
Biogen plots 30% Leqembi field force bump, omnichannel campaigns
Apr 25, 2024 6:58am
Eisai's Leqembi launch tripped up on a host of challenges
Feb 27, 2024 9:20am
